Metabolite Profiles During Oral Glucose Challenge

Citation
Ho, Jennifer E., Martin G. Larson, Ramachandran S. Vasan, Anahita Ghorbani, Susan Cheng, Eugene P. Rhee, Jose C. Florez, Clary B. Clish, Robert E. Gerszten, and Thomas J. Wang. 2013. “Metabolite Profiles During Oral Glucose Challenge.” Diabetes 62 (8): 2689-2698. doi:10.2337/db12-0754. http://dx.doi.org/10.2337/db12-0754.

Published Version
doi:10.2337/db12-0754

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785867

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Metabolite Profiles During Oral Glucose Challenge
Jennifer E. Ho,1,2 Martin G. Larson,1,3 Ramachandran S. Vasan,1,4 Anahita Ghorbani,5
Susan Cheng,1,6 Eugene P. Rhee,7,8,9 Jose C. Florez,10,11,12 Clary B. Clish,9 Robert E. Gerszten,5,7,9
and Thomas J. Wang1,5,7

To identify distinct biological pathways of glucose metabolism, we conducted a systematic evaluation of biochemical changes after an oral glucose tolerance test (OGTT) in a community-based population. Metabolic profiling was performed on 377 nondiabetic Framingham Offspring cohort participants (mean age 57 years, 42% women, BMI 30 kg/m²) before and after OGTT. Changes in metabolic levels were evaluated with paired Student t tests, cluster-based analyses, and multivariable linear regression to examine differences associated with insulin resistance. Of 110 metabolites tested, 91 significantly changed with OGTT (P ≤ 0.0005 for all). Amino acids, β-hydroxybutyrate, and tricarboxylic acid cycle intermediates decreased after OGTT, and glycolysis products increased, consistent with physiological insulin actions. Other pathways affected by OGTT included decreases in serotonin derivatives, urea cycle metabolites, and B vitamins. We also observed an increase in conjugated, and a decrease in unconjugated, bile acids. Changes in β-hydroxybutyrate, isoleucine, lactate, and pyridoxate were blunted in those with insulin resistance. Our findings demonstrate changes in 91 metabolites representing distinct biological pathways that are perturbed in response to an OGTT. We also identify metabolite responses that distinguish individuals with and without insulin resistance. These findings suggest that unique metabolic phenotypes can be unmasked by OGTT in the prediabetic state. Diabetes 62:2689–2698, 2013

D iabetes affects >1 in 10 adults 20 years of age or older in the U.S., and more than one-third of all adults have prediabetes (1). Changes in traditional measures of glucose and insulin metabolism are known to occur years before the diagnosis of diabetes is made (2). Using high-throughput profiling of metabolic status, we have shown that elevations in plasma branched-chain and aromatic amino acids are also able to predict future diabetes in otherwise normoglycemic, healthy adults (3). Similarly, lipid profiling has demonstrated novel perturbations in triacylglycerol distribution that signal future diabetes risk (4). These findings highlight how emerging technologies are able to broaden our perspective on early disease states, potentially lending insights into biological mechanisms that underlie diabetes and metabolic disease. Characterizing early metabolic changes may also lead to the early identification of at-risk individuals and may prompt the initiation of proven preventive strategies (5).

The oral glucose tolerance test (OGTT) provides a dynamic view of glucose and insulin physiology and has been widely used for decades to diagnose diabetes (6,7). Therefore, we conducted a systematic evaluation of biochemical changes after OGTT in a community-based population, with the goal of providing a broad view of the metabolic response to a glucose challenge. An important advantage of profiling plasma samples before and after glucose ingestion is that each individual is able to serve as their own biological control. In addition to attenuating noise attributable to interindividual variation, this approach limits confounding effects of diet, medications, and other inputs that impact the human metabolome. We used a liquid chromatography/mass spectrometry (LC/MS)-based platform that allowed highly specific identification of small molecules in a targeted manner. In prior pilot studies, our group has shown that metabolite excursions with OGTT revealed a switch from catabolism to anabolism, largely attributable to insulin actions (8). In the current study, we sought to evaluate perturbations with OGTT in an expanded panel of metabolites and in a more comprehensive population-based sample with a high propensity for the development of diabetes, and to investigate these changes in individuals with and without insulin resistance.

RESEARCH DESIGN AND METHODS

Study sample. The Framingham Heart Study (FHS) Offspring cohort is a prospective, observational, community-based cohort (9). The children (and their spouses) of FHS participants were recruited in 1971 and have been followed with serial examinations approximately every 4 years. Sample selection procedures have previously been described (3). In brief, study participants included in this analysis attended the fifth examination (1995–1998), and they underwent metabolic profiling on pre- and post–glucose challenge samples. A total of 377 individuals free of diabetes were included in this analysis. Participants provided informed consent, and the study protocol was approved by the institutional review board at Boston University Medical Center.

Clinical assessment. Subjects underwent a 24-h, 75-g OGTT after a 12-h overnight fast. Blood samples were obtained before and after OGTT. Diabetes was defined as a fasting glucose ≥126 mg/dL, nonfasting blood glucose ≥200 mg/dL, or the use of insulin or other hypoglycemic medications. Hypertension was defined as a systolic blood pressure (SBP) ≥140 mmHg, a diastolic blood pressure ≥90 mmHg, or current use of medication to treat hypertension. Participants smoking cigarettes regularly during the prior year were considered current smokers. The homeostasis model assessment of insulin resistance (HOMAIR) was calculated as fasting insulin (µIU/mL) × fasting glucose

From the 1Framingham Heart Study of the National Heart, Lung, and Blood Institute and Boston University School of Medicine, Framingham, Massachusetts; the 2Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, Boston, Massachusetts; the 3Department of Mathematics and Statistics, Boston University, Boston, Massachusetts; the 4Division of Cardiology and Preventive Medicine, Department of Medicine, Boston University, Boston, Massachusetts; the 5Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; the 6Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; the 7Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; the 8Renal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; the 9Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts; the 10Center for Human Genetic Research and Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston, Massachusetts; the 11Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts; and the 12Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Corresponding author: Thomas J. Wang, tjwang@partners.org.

Received 6 June 2012 and accepted 29 January 2013.

DOI: 10.2337/db12-0754

This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0754/-/DC1.

R.E.G. and T.J.W. contributed equally to this study.

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

See accompanying commentary, p. 2651.
Metabolic syndrome was defined as the presence of any three of the following five criteria (11): waist circumference ≥40 inches in men or ≥35 inches in women, triglycerides ≥150 mg/dL or treatment with a fibrat or niacin, HDL cholesterol <40 mg/dL in men or <50 mg/dL in women, or treatment with a fibrat or niacin, SBP ≥130 mmHg or diastolic blood pressure ≥85 mmHg or drug treatment for hypertension, or fasting glucose ≥100 mg/dL or drug treatment for osteoporosis.

Metabolic profiling. Blood samples were collected after an overnight fast, both immediately prior to and 2 h after administration of a standard 75-g OGTT. Samples were immediately centrifuged and stored at −80°C until assayed. The details of the LC/MS platform used to profile analytes have been previously described (3). In brief, data were acquired using a 4000 QTRAP triple quadrupole mass spectrometer (Applied Biosystems/Sciex, Foster City, CA) and a multiplexed LC system consisting of two 1200 Series pumps (Agilent Technologies) and an HTS PAL autosampler (Leap Technologies). Polar plasma metabolites were measured using hydrophilic interaction chromatography and tandem MS with electrospray ionization and multiple reaction monitoring scans in the positive ion mode as previously detailed (3). We also performed a complete analysis of small molecules preferentially ionized using negative mode electrospray ionization under basic conditions and used hydrophilic interaction chromatography to assess organic acids and other intermediary metabolites. Formic acid, ammonium acetate, and LC/MS-grade solvents (Sigma-Aldrich) were used, and samples were prepared by adding 120 μL of extraction solution (30% methanol plus the internal standards insulin−$^3$H, thymine−d$_4$, and glycodeoxycholate−d$_4$) to 30 μL of plasma. The samples were centrifuged (10 min, 10,000 rpm, 4°C) and supernatants were injected directly. For quality control, internal standard peak areas were monitored and labeled samples with peak areas differing by >2 SD from the group mean were reanalyzed. For this analysis, 54% of the metabolites had a coefficient of variation ≤10%, and 74% had a coefficient of variation ≤20%.

Statistical analysis. Baseline characteristics were summarized by insulin resistance status. Metabolites with >20% missing or undetectable values were excluded. The metabolites were analyzed. Metabolite levels were log-transformed due to right-skewed distribution, and paired Student *t* tests were conducted to examine the differences between post- and pre-OGTT metabolite levels. To account for multiple testing, a Bonferroni-corrected threshold, *P* < 0.05/110 = 0.0005, was used to define a statistically significant change in metabolite levels with glucose challenge. Pearson correlation coefficients were calculated to identify groupings of metabolites.

Metabolites with a >1.2-fold change (based on the ratio of the log-transformed metabolites) after OGTT were selected to test for differences between subsets with and without insulin resistance. To minimize multiple hypothesis testing, metabolites within the same grouping were only selected if there was low-moderate correlation between metabolites (defined as absolute *r* < 0.4). Multivariable linear regression was used to test differences in OGTT metabolite changes based on HOMA-IR and between groups with and without insulin resistance; models were first adjusted for age and sex and further adjusted for BMI. Results were deemed significant at a Bonferroni-corrected threshold, *P* < 0.05/27 = 0.002. Least squares-adjusted mean differences were graphed. To explore whether differences in metabolite excursion in insulin-resistant individuals were potentially mediated by insulin effects, we examined the relationship of insulin excursion during OGTT and the corresponding metabolite excursion using multivariable linear regression.

In secondary analyses, metabolites with significant changes during glucose challenge were then included in a cluster-based analysis. The change in metabolite with OGTT (∆) was defined as the log-post-OGTT metabolite level minus the log-pre-OGTT metabolite level. The ∆ in metabolite levels with OGTT were rank normalized using the Bloomberg method, and correlated ∆ were classified into hierarchical groupings using cluster analysis (PROC VARCLUS). Clusters were formed on the basis of principal components, using eigenvalue thresholds of 1.

A cluster score was then calculated for each participant, based on the average of the rank-normalized ∆ for metabolites within each cluster. Multivariable regression models were used to examine the association of cluster scores and metabolic traits, including insulin resistance, defined as the upper quartile of HOMA-IR in the nondiabetic participants of the Framingham Offspring cohort who attended exam 5; impaired glucose tolerance, defined as a 2-h post-OGTT glucose of 140–199 mg/dL; and impaired fasting glucose, defined as a fasting glucose 100–125 mg/dL. Models were first adjusted for age and sex and further adjusted for BMI. The study sampling scheme was accounted for in PROC GLIMMIX. For clusters with significant Bonferroni-adjusted *P* values, the same regression models were performed on individual metabolite ∆ to examine the association of individual metabolites with each glycemic trait.

All analyses were conducted using SAS 9.3 (Cary, NC), and PROC GLIMMIX was used to account for the sampling scheme.

### RESULTS

A total of 377 subjects (mean age 57 years, 42% women) were included in this analysis. Due to the selection of a sample with a high propensity for the development of diabetes, half of the sample met the definition of insulin resistance, with HOMA-IR in the top quartile of the full nondiabetic FHS Offspring sample. Insulin-resistant individuals tended to have a higher prevalence of metabolic syndrome or features of the metabolic syndrome (Table 1).

### Insulin levels increased by 65 ± 55 μIU/mL (*P* < 0.0001) 2 h after glucose challenge, and glucose levels increased by 17 ± 30 mg/dL (*P* < 0.0001) at 2 h post-OGTT in the overall sample. Insulin and glucose excursion with OGTT were positively correlated (*r* = 0.53, *P* < 0.0001). Participants with insulin resistance had higher baseline insulin levels, with higher insulin and glucose excursion after OGTT, compared with those who were not insulin resistant (insulin increased by 89 ± 63 vs. 41 ± 31 μIU/mL, *P* < 0.0001; glucose increased by 24 ± 29 vs. 10 ± 29 mg/dL, *P* < 0.0001).

Of the 110 metabolites that were detectable in at least 80% of the sample, 91 significantly increased or decreased in level after the glucose challenge (*P* ≤ 0.0005 for all). The majority of metabolites decreased in response to OGTT (Table 2), whereas a few increased in response to glucose challenge (Table 3). The largest relative decreases were seen in β-hydroxybutyrate, which decreased by more than fourfold after glucose challenge, and serotonin, which decreased more than twofold. By contrast, the largest increase was in hippurate (a known derivative of the preservative benzoic acid found in gluconol, the drink used during OGTT) (12), which increased more than fourfold, and phosphoglycerate, which increased by ~50%. Older men had a higher prevalence of metabolic syndrome, with HOMA-IR in the top quartile of the full nondiabetic FHS Offspring sample.

### Laboratory characteristics

| Clinical characteristics | Total (n = 377) | Normal (n = 189) | Resistant (n = 188) |
|--------------------------|----------------|------------------|---------------------|
| Age (years)              | 56.5 (8.8)     | 56.3 (8.8)       | 56.7 (8.8)          |
| Women, %                 | 42             | 44               | 40                  |
| BMI (kg/m$^2$)           | 30.2 (5.3)     | 28.4 (4.6)       | 32.0 (5.3)          |
| Waist circumference (cm) | 101 (13)       | 97 (12)          | 105 (12)            |
| SBP (mmHg)               | 133 (18)       | 132 (19)         | 134 (17)            |
| Antihypertensive treatment, % | 30           | 25               | 35                  |
| Current smoker, %        | 16             | 17               | 16                  |
| Metabolic syndrome, %    | 67             | 51               | 82                  |
| Fasting glucose (mg/dL)  | 105 (9)        | 103 (9)          | 106 (8)             |
| 2-h glucose (OGTT) (mg/dL) | 122 (31)   | 113 (30)         | 131 (29)            |
| Fasting insulin (μIU/mL) | 12.8 (9.4)     | 6.4 (2.8)        | 19.2 (9.4)          |
| HOMA-IR                  | 3.3 (2.5)      | 1.6 (0.7)        | 5.0 (2.5)           |
| Total cholesterol (mg/dL) | 211 (36)      | 213 (39)         | 208 (33)            |
| HDL cholesterol (mg/dL)  | 45 (13)        | 49 (14)          | 41 (11)             |
| Triglycerides (mg/dL)    | 172 (105)      | 144 (86)         | 200 (114)           |

Data are presented as mean (SD) unless otherwise indicated.
| Metabolite          | Pathway group     | Mean change* | SD   | Fold change |
|---------------------|-------------------|--------------|------|-------------|
| β-Hydroxybutyrate   | Ketone            | −1.51        | 0.72 | 4.51        |
| Serotonin           | Tryptophan derivative | −0.85       | 0.83 | 2.33        |
| Hypoxanthine        | Purine            | −0.78        | 0.93 | 2.17        |
| Xanthine            | Purine            | −0.52        | 0.57 | 1.68        |
| Citrulline          | Urea cycle        | −0.50        | 0.15 | 1.65        |
| Guanosine diphosphate | Purine           | −0.49        | 0.72 | 1.63        |
| Isoleucine          | Amino acid        | −0.47        | 0.14 | 1.60        |
| Leucine             | Amino acid        | −0.45        | 0.15 | 1.57        |
| Inosine             | Purine            | −0.40        | 0.49 | 1.49        |
| Xanthurenate        | Amino acid metabolite | −0.39       | 0.31 | 1.47        |
| Propionate          | Organic acid      | −0.38        | 0.42 | 1.46        |
| Guanosine monophosphate | Purine          | −0.37        | 0.66 | 1.45        |
| Methionine          | Amino acid        | −0.36        | 0.19 | 1.44        |
| Gentisate           | Amino acid metabolite | −0.34       | 0.47 | 1.41        |
| Tyrosine            | Amino acid        | −0.34        | 0.14 | 1.41        |
| Cholate             | Bile acid         | −0.33        | 0.82 | 1.40        |
| Adenosine monophosphate | Purine          | −0.33        | 0.76 | 1.39        |
| Hydroxyproline      | Amino acid        | −0.31        | 0.15 | 1.37        |
| Asparagine          | Amino acid        | −0.31        | 0.24 | 1.36        |
| Adenosine diphosphate | Purine           | −0.29        | 0.84 | 1.33        |
| Salicylurate        |                   | −0.28        | 0.46 | 1.33        |
| Uridine diphosphate | Pyrimidine        | −0.27        | 0.43 | 1.31        |
| Niacinamide         |                   | −0.27        | 0.40 | 1.31        |
| Threonine           | Amino acid        | −0.27        | 0.11 | 1.31        |
| Aspartate           | Amino acid        | −0.27        | 0.30 | 1.31        |
| Phenylalanine       | Amino acid        | −0.26        | 0.14 | 1.30        |
| Ornithine           | Urea cycle        | −0.25        | 0.25 | 1.29        |
| Aminoacidipate      | Amino acid metabolite | −0.25       | 0.23 | 1.28        |
| Serine              | Amino acid        | −0.24        | 0.17 | 1.27        |
| Orotic             | Vitamin           | −0.24        | 0.28 | 1.27        |
| Valine              | Amino acid        | −0.23        | 0.10 | 1.26        |
| Uridine monophosphate | Pyrimidine        | −0.23        | 0.46 | 1.25        |
| Cystathionine       | Amino acid metabolite | −0.22       | 0.32 | 1.25        |
| Arginine            | Amino acid        | −0.22        | 0.35 | 1.24        |
| Pyridoxate          | Vitamin           | −0.20        | 0.16 | 1.22        |
| Deoxycholates       | Bile acid         | −0.19        | 0.41 | 1.21        |
| Xanthosine          |                   | −0.17        | 0.25 | 1.19        |
| Lysine              | Amino acid        | −0.17        | 0.14 | 1.18        |
| Histidine           | Amino acid        | −0.17        | 0.14 | 1.18        |
| Tryptophan          | Amino acid        | −0.16        | 0.14 | 1.17        |
| α-Hydroxybutyrate   | Organic acid      | −0.16        | 0.17 | 1.17        |
| ADMA/SDMA           |                   | −0.15        | 0.15 | 1.16        |
| Ribose/ribulose phosphate | Sugar          | −0.15        | 0.40 | 1.16        |
| Thiamine            |                   | −0.15        | 0.70 | 1.16        |
| 5-HIAA              | Tryptophan derivative | −0.14       | 0.39 | 1.15        |
| Glycine             | Amino acid        | −0.14        | 0.17 | 1.15        |
| Glutamate           | Amino acid        | −0.14        | 0.21 | 1.15        |
| NMMA                |                   | −0.14        | 0.18 | 1.15        |
| Proline             | Amino acid        | −0.14        | 0.09 | 1.15        |
| Taurine             |                   | −0.14        | 0.12 | 1.14        |
| Hydroxyphenylacetate | Amino acid metabolite | −0.13       | 0.19 | 1.13        |
| Indole propionate   | Amino acid metabolite | −0.12       | 0.25 | 1.13        |
| Oxalate             | Dicarboxylic acid | −0.12        | 0.21 | 1.12        |
| Fumarate/maleate    | TCA cycle         | −0.11        | 0.22 | 1.12        |
| Flavin mononucleotide | Vitamin          | −0.11        | 0.44 | 1.12        |
| Aconitate           | TCA cycle         | −0.10        | 0.21 | 1.11        |
| Glutamine           | Amino acid        | −0.10        | 0.26 | 1.10        |
| Pantothenate        | Vitamin           | −0.09        | 0.15 | 1.10        |
| Uridine             | Pyrimidine        | −0.09        | 0.16 | 1.10        |
| Trimethylamine      |                   | −0.09        | 0.24 | 1.09        |
| Isocitrate          | TCA cycle         | −0.08        | 0.18 | 1.08        |
| Methyladipate/pimelate | Dicarboxylic acid | −0.07        | 0.18 | 1.07        |
| Glucuronate         | Sugar             | −0.07        | 0.23 | 1.07        |

Continued on next page
age was associated with greater increases in glucose/fructose/lactose with OGTT ($P = 0.0003$). After adjustment for age and baseline metabolite levels, women had greater decreases in citrulline and xanthosine and greater increases in bile acids, phosphoenolpyruvate, and glucose/fructose/lactose with glucose challenge when compared with men ($P < 0.0005$ for all) (Supplementary Table 1).

Correlated metabolites reflect biological pathways. In analyses using a cluster-based approach, we found that groupings of metabolites whose baseline concentrations correlated, or whose responses to glucose challenge correlated, also reflected common underlying biological groupings. For example, baseline amino acid concentrations, as well as their responses to OGTT, were highly correlated with each other (Supplementary Tables 2 and 3 and Fig. 1).

Insulin actions on known metabolic pathways. Changes in metabolite levels in response to glucose challenge appeared to be consistent across metabolic pathways (Fig. 2), highlighting the multiple physiological actions of insulin. Decreases in all amino acids and related metabolites provided evidence of decreased proteolysis. Similarly, a decrease in β-hydroxybutyrate and tricarboxylic acid (TCA) cycle intermediates was consistent with inhibition of ketogenesis and TCA cycle flux. In contrast, products of glycolysis increased after glucose challenge. Our findings also show a decrease in nitrogenous bases, including purines and pyrimidines, in response to glucose challenge, consistent with insulin-mediated stimulation of DNA and purine biosynthesis across different tissues as seen in previous experimental studies (13,14).

Insulin actions on novel biological pathways. We found consistent changes in several biological pathways that are less established in relation to glucose and insulin metabolism (Fig. 3). Serotonin and its precursors/derivatives, including 5-hydroxyindoleacetic acid (5-HIAA) and tryptophan, all decreased after glucose challenge. Metabolites of the urea cycle, including citrulline, ornithine, and arginine, all decreased. Nucleic acids and related metabolites decreased as well in response to OGTT. We also observed decreases in a number of derivatives or cofactors related to the B vitamins, a group of water-soluble vitamins essential to cellular metabolism: niacinamide, the amide of nicotinic acid (vitamin B3/niacin), is important in various oxidation-reduction reactions; pyridoxate, an enzyme in the family of

**TABLE 2**

Continued

| Metabolite          | Pathway group              | Mean change* | SD    | Fold change |
|---------------------|----------------------------|--------------|-------|-------------|
| Alanine             | Amino acid                 | -0.07        | 0.13  | 1.07        |
| Sorbitol            | Sugar                      | -0.07        | 0.19  | 1.07        |
| Quinolinate         | Amino acid metabolite      | -0.07        | 0.16  | 1.07        |
| Hydroxybutyrate     | Organic acid               | -0.06        | 0.25  | 1.07        |
| Dimethylglycine     | Methyl                     | -0.05        | 0.12  | 1.06        |
| FIP/F6P/G1P/G6P     | Glycolysis                 | -0.05        | 0.28  | 1.05        |
| Adipate             | Dicarboxylic acid          | -0.05        | 0.23  | 1.05        |
| Suberate            | Dicarboxylic acid          | -0.05        | 0.19  | 1.05        |
| Sebacate            | Dicarboxylic acid          | -0.04        | 0.19  | 1.04        |
| Urate               | Purine                     | -0.03        | 0.10  | 1.03        |

ADMA, asymmetric dimethylarginine; FIP, fructose 1-phosphate; F6P, fructose 6-phosphate; G1P, glucose 1-phosphate; G6P, glucose 6-phosphate; NMMA, N-monomethylarginine; SDMA, symmetric dimethylarginine. *Mean change represents log-post-OGTT value minus log-pre-OGTT value.

**TABLE 3**

Metabolites that increased after glucose challenge (paired Student $t$ test, $P < 0.0001$ for all)

| Metabolite            | Group                        | Mean change* | SD    | Fold change |
|-----------------------|------------------------------|--------------|-------|-------------|
| Hippurate             | Amino acid metabolite        | 1.53         | 0.80  | 4.63        |
| Phosphoglycerate      | Glycolysis                   | 0.39         | 0.61  | 1.48        |
| Taurodeoxycholates    | Bile acid                    | 0.34         | 0.86  | 1.41        |
| Glycodeoxycholates    | Bile acid                    | 0.30         | 0.82  | 1.35        |
| α-Glycerophosphate    | Glycolysis                   | 0.30         | 0.49  | 1.35        |
| Taurocholate          | Bile acid                    | 0.24         | 0.84  | 1.27        |
| Glycococholate        | Bile acid                    | 0.15         | 0.63  | 1.17        |
| Glycerylphosphocholine| Methyl                       | 0.14         | 0.38  | 1.16        |
| Lactate               | Glycolysis                   | 0.13         | 0.22  | 1.14        |
| Phosphoenolpyruvic acid| Glycolysis                  | 0.10         | 0.33  | 1.11        |
| Phosphocreatine       |                              | 0.10         | 0.32  | 1.10        |
| Glucose/fructose/lactose| Sugar                      | 0.06         | 0.24  | 1.06        |
| Inositol              | Sugar                        | 0.06         | 0.20  | 1.06        |
| Creatine              |                              | 0.05         | 0.14  | 1.05        |
| Fructose/glucose/galactose| Sugar                  | 0.04         | 0.14  | 1.05        |
| Carnitine             |                              | 0.03         | 0.08  | 1.03        |
| Choline               | Methyl                       | 0.03         | 0.12  | 1.03        |
| Betaine               | Methyl                       | 0.03         | 0.08  | 1.03        |

*Mean change represents log-post-OGTT value minus log-pre-OGTT value.
oxidoreductases, plays a crucial role in vitamin B6 metabolism; thiamine (vitamin B1) is a coenzyme in glucose and amino acid metabolism; flavin mononucleotide is a derivative of riboflavin (vitamin B2) and serves as a cofactor for a variety of oxidoreductases; and pantothenate (vitamin B5) is an essential cofactor for CoA synthesis and metabolism of proteins, carbohydrates, and fats. Lastly, we observed an increase in conjugated bile acids and a concomitant decrease in unconjugated bile acids in response to the glucose challenge.

Effect of insulin resistance and other glycemic traits on metabolite excursions. A total of 27 uncorrelated ($r < 0.4$) metabolites had a $>1.2$-fold change after OGTT. For five of these metabolites, the excursion after OGTT was different in participants with normal insulin levels compared with insulin-resistant individuals, including $\beta$-hydroxybutyrate, isoleucine, lactate, orotate, and pyridoxate (Table 4). The excursion of all metabolites except orotate was blunted in insulin-resistant, compared with noninsulin-resistant, individuals (Fig. 4). Of these metabolites, changes in lactate, but not the other metabolites, were associated with insulin excursion during OGTT in the overall sample in exploratory analyses ($P < 0.0001$ after adjustment for age, sex, and insulin resistance status) and remained associated after exclusion of insulin-resistant individuals ($P = 0.0005$). When examined as a continuous variable, additional suggestive differences were observed according to HOMA-IR in taurodeoxycholates, niacinamide, and ornithine, with a blunted response in those with greater insulin resistance (Supplementary Table 4).

In secondary analyses using a cluster-based approach, changes in hydroxyphenylacitate and phosphoenolpyruvate with OGTT had suggestive associations with fasting glucose. Glucose/fructose/lactose, fructose/glucose/galactose,

---

FIG. 1. Heat map of correlated metabolite changes with glucose challenge.
and hippurate had significant associations with 2-h post-OGTT glucose, and β-hydroxybutyrate, tryptophan, α-hydroxybutyrate, and ornithine had suggestive associations (Supplementary Table 5).

DISCUSSION

Using a systematic approach, we have demonstrated perturbations in numerous metabolic and biological pathways in response to a glucose challenge. Many pathways represent expected responses to the actions of insulin, including alterations in glycolysis, lipolysis, ketogenesis, and proteolysis. However, we also observed consistent effects of glucose loading on a number of biological pathways that have not previously been well described. Specifically, the neurotransmitter serotonin (and related metabolites) was suppressed more than twofold in response to glucose challenge. In addition, we observed a consistent decrease in the precursors or derivatives related to the B vitamins after OGTT. Lastly, we identified differences in metabolite responses between individuals with and without insulin resistance, indicating that changes in metabolic phenotypes may be unmasked by OGTT in the prediabetic state.

To our knowledge, ours is the largest study to date to describe the physiological changes in metabolites after OGTT. Several smaller studies have reported changes in metabolites with glucose challenge in humans (8,15,16) and animal models (17). Our group previously examined metabolic profiling in response to glucose challenge in healthy university students, with validation in a middle-aged subset of 50 participants of the FHS (8). This study demonstrated significant changes in 18 metabolites, with some differences in metabolite excursions related to baseline fasting insulin levels. We now extend these findings to a far greater sample size and demonstrate significant changes in >90 metabolites representing a number of distinct biological pathways that are involved in the intrinsic biological response to a glucose challenge.

There is a growing body of evidence demonstrating a postprandial or postglucose increase in circulating conjugated bile acids (8,16). Glucose ingestion is known to stimulate the release of cholecystokinin, signaling gallbladder contraction and release of bile into the enterohepatic circulation (18). Experimental evidence suggests that both glucose and insulin rapidly induce cytochrome P-450 enzyme cholesterol 7α-hydroxylase (CYP7A1) gene expression,
thus augmenting the rate-limiting enzyme of “classical” bile acid synthesis (19,20). Metabolic status also seems to regulate expression of the farnesoid X receptor, a transcription factor that controls bile acid synthesis (21), and expansion of the bile acid pool in turn may be linked to improved glucose homeostasis (22). We not only demonstrate a robust increase in conjugated bile acids in response to glucose challenge but also show a simultaneous decrease in unconjugated bile acids, suggesting that conjugation, a process catalyzed by bile acid CoA:amino acid N-acyltransferase (21), may be affected by postprandial increases in glucose and/or insulin. Gut microbiota are known to modify bile acids in a variety of different ways, including deconjugation, dehydroxylation, oxidation, and sulfation (23), and altered bile acid profiles have previously been linked to diabetes in a case-control study (24). It is possible that alterations in gut microbial metabolism may have affected the bile acid profile post–glucose challenge.

One of the notable and unexpected findings of our study was a consistent decrease in vitamins B1, B2, B3, B5, and B6 after glucose challenge. The B vitamins are a group of water-soluble vitamins essential to cellular metabolism. Interestingly, this observation can be considered in the context of a well-known clinical observation pertaining to thiamine (B1), an essential cofactor for pyruvate dehydrogenase, an enzyme linking glycolysis and the citric acid cycle, as well as α-ketoglutarate dehydrogenase, an important enzyme in the citric acid cycle (25). Thiamine deficiency is the cause of Wernicke’s encephalopathy, an acute neurological disorder seen in the setting of chronic excessive alcohol abuse. It has long been recognized that symptoms of Wernicke’s encephalopathy can be precipitated rapidly after the institution of intravenous glucose therapy in susceptible individuals (26). We now show that a measurable decrease in thiamine occurs even in ostensibly healthy individuals after glucose ingestion. The mechanism for this decrease is unclear, although it may be that increased glycolysis after glucose ingestion drives down circulating plasma thiamine levels. Dynamic changes in the other B vitamins after glucose challenge are of equal interest, as many play essential roles in metabolic pathways affected by insulin action, including amino acid metabolism (B6), gluconeogenesis (B6), the TCA cycle (B5), and various redox reactions (B2 and B3).

We observed a more than twofold decrease in serotonin levels after glucose challenge, as well as a concomitant decrease in its precursor tryptophan and its main metabolite.
5-HIAA. Serotonin is a neurotransmitter that plays an important role in energy and glucose homeostasis, an effect that is mediated via central autonomic pathways in the midbrain, as well as by peripheral release of serotonin from gastrointestinal enterochromaffin cells (27). In experimental studies, genetic deletion of the serotonin receptor 5-HT2c produced insulin resistance and type 2 diabetes (28), and 5-HT2c agonists improved peripheral insulin action (29). In turn, the effect of glucose load on circulating serotonin levels has not been well described. A previous study in 100 healthy individuals measured plasma neurotransmitters in response to OGTT and noted noradrenergic over parasympathetic predominance at 2 h (30). Another study showed postprandial increases in serotonin levels after ingestion of a meal in healthy volunteers (31). These results may contrast with our findings due to differences in the ingested tryptophan content. Serotonin synthesis is sensitive to the availability of tryptophan (32), and it may be that decreases in serotonin follow decreased tryptophan concentrations in response to glucose challenge in our study.

We observed five metabolites with differential changes in response to glucose challenge in insulin-resistant individuals. Interestingly, insulin resistance was associated with a blunted excursion post-OGTT for β-hydroxybutyrate, isoleucine, lactate, and pyridoxate. This confirms that suppression of ketogenesis (β-hydroxybutyrate), proteolysis (isoleucine), and increased glycolysis (lactate) is likely mediated via insulin actions, and that these effects are attenuated in the insulin-resistant state. Furthermore, greater increases in insulin during glucose challenge were associated with larger increases in lactate in individuals with normal HOMA-IR.

Interestingly, there appear to be sex differences in circulating fasting metabolite concentrations and their association with insulin action (33). We now show that there are also sex differences in the dynamic response to glucose challenge, emphasizing the potential role of hormonal factors in the regulation of glucose homeostasis and diabetes pathogenesis (34).

It is thought that impaired fasting glucose predominantly reflects a defect in early insulin secretion during OGTT and hepatic insulin resistance, and impaired glucose tolerance reflects both early and late defects in insulin secretion during OGTT, and mostly insulin resistance at the level of skeletal muscle (35). In exploratory analyses, we found a blunted decrease in β-hydroxybutyrate, α-hydroxybutyrate, tryptophan, and ornithine in individuals with higher 2-h post-OGTT glucose, suggesting that suppression of ketogenesis, proteolysis, and the urea cycle is blunted in these individuals. This may possibly reflect a late-phase defect in insulin secretion, although further studies are needed to substantiate these findings.

Several limitations of the study deserve mention. Although many metabolite changes were in concert with known physiological actions of insulin, it is not possible in our observational study to discern whether perturbations could also have been due to effects of glucose excursion during OGTT. Furthermore, enteric microbiota can influence
circulating metabolites (36), and it may be that dynamic changes seen with glucose challenge could in part be due to effects on intestinal microbes, rather than pure insulin effects. For example, plasma hippurate concentrations may be elevated due to gut microbial metabolism of phenylalanine (37). It is possible that glucose ingestion stimulated intestinal microbial metabolism, resulting in increased hippurate levels in our study, although other metabolites of microbial metabolism (including propionate, dimethylglycine, trimethylamine, and indoxylsulfate) (8) decreased with glucose challenge. The effect of glucose challenge on gut microbial contributions to changes in plasma metabolites requires further study. Decreases in plasma metabolites could be in part related to a dilutional effect with the volume ingested during glucose challenge. However, in a previous study that diluted the 75-g OGTT by up to threefold, most differences in measured glucose were observed early in the test, with no difference in 2-h values, indicating that this effect may be minimal in our study, which only measured metabolites at the 2-h time point (38). Furthermore, the varying directionality and broad range in change among different analytes would argue against a simple dilutional effect. We used a targeted approach with a combination of LC and tandem MS to identify metabolites. Although this system is less biased than other techniques, such as nuclear magnetic resonance spectroscopy, it allowed for highly specific identification of metabolites. We were not able to provide absolute concentrations for all metabolites, and studies of absolute quantitation of metabolites remain important areas of future investigation. Lastly, the FH is a predominantly Caucasian middle-aged cohort, and the sample in this study included individuals with a high propensity for the development of diabetes, with a large proportion meeting the criteria for insulin resistance; therefore, our findings may not be generalizable to other populations.

In summary, we found changes in distinct metabolic and biological pathways in response to glucose challenge. Although alterations in glycosylation, lipolysis, ketogenesis, and proteolysis are known effects of insulin action, we also found consistent changes in the serotonergic system and multiple members of the B vitamins after glucose challenge. These findings may further elucidate the metabolic pathways regulating glucose homeostasis. We also identified differences in metabolite responses between individuals with normal insulin and insulin resistance, indicating that changes in metabolic phenotypes associated with the prediabetic state may be unmasked by OGTT. Further studies investigating the distinct biological pathways identified in our study may lead to a better understanding of the adaptive versus maladaptive processes involved in glucose and insulin metabolism.

ACKNOWLEDGMENTS
This work was supported by the National Institutes of Health (R01-HC-25195 and R01-DK-HL-081572), the American Heart Association, the Leducq Foundation, and the Ellison Foundation.

R.E.G., R.S.V., M.G.L., and T.J.W. were named as co-inventors on a patent application relating to amino acid predictors of diabetes. J.C.F. has received consulting honoraria from Novartis, Eli Lilly, and Pfizer. No other potential conflicts of interest relevant to this article were reported.

J.E.H., R.E.G., and T.J.W. conceived the study, designed experiments, analyzed data, and wrote the manuscript.

M.G.L., R.S.V., A.G., and S.C. helped in experimental design, analyzed data, and assisted in manuscript generation. E.P.R. and C.B.C. developed the metabolic profiling platform, performed MS experiments, analyzed the data, and assisted in manuscript generation. J.C.F. helped in manuscript generation. J.E.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

REFERENCES
1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. Tabuk AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009;373:2215–2221
3. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:453–453
4. Ehsan EP, Cheng S, Larson MG, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011;121:1402–1411
5. Tuomilehto J, Lindstrom J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1345–1350
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl. 1):S62–S69
7. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294:E15–E26
8. Shaham O, Wei R, Wang TJ, et al. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 2008;4:214
9. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979;109:283–287
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419
11. Grundy SM, Cleeman JJ, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752
12. Kubota K, Ishizaki T. Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol 1991;41:363–368
13. Tsuchiya M, Yoshikawa H, Itakura M, Yamashita K. Increased de novo purine synthesis by insulin through selective enzyme induction in primary cultured rat hepatocytes. Am J Physiol 1990;258:C841–C848
14. Vintsers IV, Berliner JA, Beck DW, Maxwell K, Bready JV, Cancilla PA. Insulin stimulates DNA synthesis in cerebral microvessel endothelium and smooth muscle. Diabetes 1985;34:964–969
15. Wopereis S, Ruhbing CM, van Erik MJ, et al. Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS ONE 2009;4:e4530
16. Zhao X, Peter A, Frütsche J, et al. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab 2009;296:E384–E393
17. Lin S, Yang Z, Liu H, Tang L, Cai Z. Beyond glucose: metabolic shifts in diabetes. Diabetes 2011;62:2224–2233
18. Liddell RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985;75:1144–1152
19. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147–191
20. Li T, Fracil JM, Boehne S, et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol Chem 2012;287:1880–1897
21. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137–174
22. Watanabe M, Horai Y, Houten SM, et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 2011;286:20913–20920
23. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241–259
24. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010;5:e13953
25. Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Alternat Med 2006;3:49–59
26. Reuler JB, Girard DE, Cooney TG. Current concepts. Wernicke’s encephalopathy. N Engl J Med 1985;312:1035–1039
27. Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev Mol Med 2007;9:1–24
28. Bonasera SJ, Tecott LH. Mouse models of serotonin receptor function: toward a genetic dissection of serotonin systems. Pharmacol Ther 2000;88:133–142
29. Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab 2007;6:398–405
30. Lecin F, van der Dijs B, Lecin M, et al. Effects of an oral glucose load on plasma neurotransmitters in humans: involvement of REM sleep? Neuropsychobiology 1992;26:4–11
31. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34–43
32. Best J, Nijhout HF, Reed M. Serotonin synthesis, release and reuptake in terminals: a mathematical model. Theor Biol Med Model 2010;7:34
33. Huffman KM, Shah SH, Stevens RD, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009;32:1678–1683
34. Franconi F, Seghieri G, Canu S, Straface E, Campesi I, Malorni W. Are the available experimental models of type 2 diabetes appropriate for a gender perspective? Pharmacol Res 2008;57:6–18
35. Nathan DM, Davidson MB, DeFronzo RA, et al.; American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753–759
36. Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol 2011;19:349–359
37. Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009;106:3698–3703
38. Sievenpiper JL, Jenkins DJ, Josse RG, Vulsan V. Dilution of the 75-g oral glucose tolerance test increases postprandial glycemic implications for diagnostic criteria. CMAJ 2000;162:993–996